Therapy of B-cell malignancies by anti–HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

A humanized IgG4 anti–HLA-DR monoclonal antibody (IMMU-114), engineered to avoid side effects associated with complement activation, was examined for binding and cytotoxicity on leukemia, lymphoma, and multiple myeloma cell lines and chronic lymphocytic leukemia (CLL) patient specimens, followed by...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Stein, Rhona, Gupta, Pankaj, Chen, Xiaochuan, Cardillo, Thomas M., Furman, Richard R., Chen, Susan, Chang, Chien-Hsing, Goldenberg, David M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2010
Schlagworte:
Lymphoid Neoplasia
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2892948/
https://ncbi.nlm.nih.gov/pubmed/20101022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-06-228288
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge